AngioDynamics, Inc. (ANGO)

Several events have impacted AngioDynamics' stock price in the past six months. On July 15, 2025, the company reported its Fiscal Year 2025 Fourth Quarter and Full-Year Financial Results. On July 16, 2025, AngioDynamics announced an equity buyback program for $15 million worth of its shares. On August 12, 2025, the company participated in the Canaccord Genuity 45th Annual Growth Conference. On October 2, 2025, AngioDynamics released its Fiscal Year 2026 First Quarter Financial Results, with the stock initially popping but then dropping due to a larger-than-expected GAAP loss. On November 10, 2025, AngioDynamics presented at the UBS Global Healthcare Conference. On January 6, 2026, the company reported its Fiscal Year 2026 Second Quarter Financial Results, beating EPS and revenue forecasts but subsequently dipping due to the announcement of CEO Jim Clemmer's intention to retire during fiscal year 2027. During this quarter, a transaction in France contributed approximately $1.4 million to adjusted EBITDA.

Analysis of stock performance suggests some seasonality in demand for AngioDynamics' products and services. Historically, buying AngioDynamics Inc. (ANGO) stock in November has shown the highest probability of a positive return (80.00%), while April has exhibited the lowest probability (20.00%). This stock performance seasonality may be influenced by various factors, including the timing of elective medical procedures or budget cycles within healthcare institutions.

AngioDynamics is a medical technology company focused on developing, manufacturing, and marketing minimally invasive medical devices, operating within the Healthcare sector, specifically in the Medical Instruments & Supplies and Health Care Equipment industries. The company's core business revolves around vascular access, peripheral vascular intervention, and interventional oncology, offering products such as atherectomy systems, thrombus management systems, tissue ablation systems, vascular access devices, and venous therapies.

AngioDynamics has a global presence, selling its products through a direct sales force in the United States and through a network of distributors in international markets, including Latin America, Europe, and Asia. The company has physical office locations in Ontario, Hong Kong, The Netherlands, Israel, and Brazil, in addition to its global headquarters in Latham, New York, and manufacturing facilities in Glens Falls and Queensbury, New York, and Massachusetts.

AngioDynamics is recognized as a market leader in minimally invasive medical devices and is committed to developing disruptive technologies to support patients and healthcare providers. The company's focus on innovation and expanding the addressable market for its products contributes positively to its reputation within the medical technology industry. There have been no widely reported negative events or controversies significantly impacting AngioDynamics' brand reputation in the past year.

Institutional investors hold a significant portion of AngioDynamics' stock, with approximately 74% to 89.43% of shares, with major holders including Divisadero Street Capital Management, LP, BlackRock, Inc., and Vanguard Group Inc. Insiders hold about 5.37% to 6.00% of the stock, while the general public or individual investors hold approximately 17% to 25.48%.